ITGAM and cancer: A variety of immunosuppressive mechanisms have been associated with poorer outcomes in cancer patients; these include elevated numbers of regulatory T cells, CD11b+ myeloid-derived suppressor cells (MDSC), CD11b+ F4/80+ tumor-associated macrophages (TAMs), and their local induction of PD-L1, IDO, arginase [52].